Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Acquired by Nordea Investment Management AB

Nordea Investment Management AB lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 220,569 shares of the biopharmaceutical company’s stock after acquiring an additional 7,593 shares during the period. Nordea Investment Management AB’s holdings in Agios Pharmaceuticals were worth $7,191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Agios Pharmaceuticals by 87.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after acquiring an additional 316,100 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $33,767,000. Seven Eight Capital LP purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $1,693,000. Finally, Edgestream Partners L.P. acquired a new position in Agios Pharmaceuticals in the 2nd quarter worth about $1,814,000.

Agios Pharmaceuticals Stock Performance

AGIO opened at $35.90 on Friday. The business’s 50 day moving average price is $46.77 and its 200 day moving average price is $45.50. The stock has a market capitalization of $2.05 billion, a PE ratio of 3.16 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.93% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on AGIO shares. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Raymond James reiterated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.